Liver transplantation for hepatocellular carcinoma and potential application of PSI;Carcinome hépatocellulaire et transplantation hépatique : rôle futur des inhibiteurs de la mTOR

Gastroenterologie Clinique et Biologique

Volumn 33, Issue SUPPL. 4, 2009, Pages

  Decaens, T ^a   Duvoux, C ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; METASTASIS INHIBITION; RECURRENCE RISK; RECURRENT CANCER; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS;

EID: 71149109710     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(09)73163-X     Document Type: Article

References (31)

1. Decaens T., Roudot-Thoraval F., Bresson-Hadni S., Meyer C., Gugenheim J., Durand F., et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 12 (2006) 7319-7325
2. Guba M., Graeb C., Jauch K.W., and Geissler E.K. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77 (2004) 1777-1782
3. Yang Q., and Guan K.L. Expanding mTOR signaling. Cell Res 17 (2007) 666-681
4. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5 (2006) 671-688
5. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
6. Luan F.L., Ding R., Sharma V.K., Chon W.J., Lagman M., and Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63 (2003) 917-926
7. Luan F.L., Hojo M., Maluccio M., Yamaji K., and Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565-1572
8. Koehl G.E., Andrassy J., Guba M., Richter S., Kroemer A., Scherer M.N., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319-1326
9. Schumacher G., Oidtmann M., Rueggeberg A., Jacob D., Jonas S., Langrehr J.M., et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11 (2005) 1420-1425
10. Zhang L., Yu Q., He J., and Zha X. Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem 262 (2004) 25-33
11. Baba HA, Wohlschlaeger J, Cicinnati VR, Hilgard P, Lang H, Sotiropoulos GC, et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 2008; in press.
12. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103 (2005) 307-312
13. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004) 8421-8425
14. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48 (2008) 83-90
15. Sieghart W., Fuereder T., Schmid K., Cejka D., Werzowa J., Wrba F., et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83 (2007) 425-432
16. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of hepatocellular carcinoma is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52
17. Semela D., Piguet A.C., Kolev M., Schmitter K., Hlushchuk R., Djonov V., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46 (2007) 840-848
18. Huynh H, Chow KP, Soo KC, Toh HC, Choo SP, Foo KF, et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2008; in press.
19. Rizell M., Andersson M., Cahlin C., Hafstrom L., Olausson M., and Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13 (2008) 66-70
20. Decaens T., Luciani A., Itti E., Hulin A., Hurtova M., Laurent A., et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. J Hepatol 48 (2008) S13
21. Catalano G., Urbani L., Biancofiore G., Bindi L., Boldrini A., Consani G., et al. Hepatic resection after liver transplantation as a graft-saving procedure: indication criteria, timing and outcome. Transplant Proc 36 (2004) 545-546
22. Kneteman N.M., Oberholzer J., Al Saghier M., Meeberg G.A., Blitz M., Ma M.M., et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10 (2004) 1301-1311
23. Elsharkawi M., Staib L., Henne-Bruns D., and Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 79 (2005) 855-857
24. Kornberg A., Kupper B., Tannapfel A., Thrum K., Wilberg J., Barthel E., et al. Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma - preliminary results. Transpl Int 21 (2008) 96-99
25. Stippel D.L., Kasper H.U., Schleimer K., Tox U., Bangard C., Holscher A.H., et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 37 (2005) 2185-2187
26. Toso C., Meeberg G.A., Bigam D.L., Oberholzer J., Shapiro A.M., Gutfreund K., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83 (2007) 1162-1168
27. Zhou J., Fan J., Wang Z., Wu Z.Q., Qiu S.J., Huang X.W., et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 12 (2006) 3114-3118
28. Zimmerman M.A., Trotter J.F., Wachs M., Bak T., Campsen J., Skibba A., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14 (2008) 633-638
29. Chen Y.B., Sun Y.A., and Gong J.P. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat Dis Int 7 (2008) 25-28
30. Badran H., Meyer C., Adam R., Plessier A., Durand F., Boillot O., et al. Moderate expansion of Milan criteria for transplantation for hepatocellular carcinoma not impact survival nor recurrence rates. J Hepatol 46 (2007) S16
31. Yao F.Y., Xiao L., Bass N.M., Kerlan R., Ascher N.L., and Roberts J.P. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7 (2007) 2587-2596